AETHLON MEDICAL INC (AEMD): Results of Operations and Financial Condition
AETHLON MEDICAL INC (AEMD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aethlon_ex9901.htm PRESS RELEASE Exhibit 99.1 Aethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update Australian oncology study advances into Cohort 3 as enrollment continues Entered the third and final dosing cohort of the Austra
How this was made
The 30-second read
Why it matters
The newest actionable facts are (1) entry into the third/final dosing cohort with the first participant treated without immediate complications, and (2) updated cash and operating expense trajectory plus an at-the-market raise after fiscal year-end.
Market read
For traders, this is a primary-source update combining a concrete clinical execution milestone (Cohort 3 dosing started) with balance-sheet and cost discipline details that can influence near-term sentiment and financing expectations.
What to watch
Cash is modest (~$5.0M) and the company still relies on continued financing; operating expense reductions help, but dilution risk can cap upside until clearer clinical/data catalysts arrive.
Background
The 8-K (Item 2.02) includes a press release covering FY2026 financials and a corporate update on Aethlon’s Hemopurifier platform, including an Australian solid-tumor oncology study with anti-PD-1 background therapy.
Ticker impact
Aethlon reports FY ended Mar 31, 2026 results and says it entered the third/final Australian oncology dosing cohort, treating the first participant in Cohort 3.
Bias modestly positive near term as investors price progress toward final dosing and data readouts; volatility likely remains high given small-study size and early-stage nature.
The filing is a primary disclosure (8-K with press release) and includes concrete trial milestone (first Cohort 3 dosing completed) and balance-sheet/operating expense figures, which typically support sentiment for clinical-stage biotech even without efficacy results.
Market effects
Reinforces investor focus on clinical-stage oncology/viral therapeutics where enrollment milestones and IP expansion can extend platform valuation narratives.
Australian trial execution milestone (Royal North Shore Hospital) may support continued confidence in site readiness and enrollment cadence.
Long COVID/coronavirus IP and expanded-access protocol references keep the platform relevant to broader global emerging-infection preparedness themes.
Counterpoint
Cohort 3 start and DSMB “no safety concerns” are execution milestones, not efficacy; the nine-to-18 patient design limits how much investors should extrapolate.
Key entities
- issuerAethlon Medical, Inc.
Clinical-stage therapeutic company developing the Hemopurifier platform; subject of the SEC 8-K disclosure.
- product_platformHemopurifier
Extracorporeal device/therapeutic platform being studied in oncology and preclinical disease expansion.
- clinical_trialAustralian oncology study (Cohorts 1-3)
Solid tumor study evaluating safety/feasibility and dosing regimens; Cohort 3 is the final dosing arm.
- oversight_bodyData Safety Monitoring Board (DSMB)
Reviewed cohort data and recommended advancing to Cohort 3 with no safety concerns.
- partnerStavro Medical
Developing a simplified blood treatment system; Aethlon reports initial compatibility testing completed.
